PepGen (PEPG)
(Delayed Data from NSDQ)
$13.16 USD
-0.49 (-3.59%)
Updated May 17, 2024 04:00 PM ET
After-Market: $13.16 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Brokerage Reports
PepGen, Inc. [PEPG]
Reports for Purchase
Showing records 1 - 20 ( 36 total )
Company: PepGen, Inc.
Industry: Medical - Biomedical and Genetics
Company: PepGen, Inc.
Industry: Medical - Biomedical and Genetics
PGN-EDODM1 has the Potential to Achieve > 30% Splicing CorrectionOur Thoughts
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: PepGen, Inc.
Industry: Medical - Biomedical and Genetics
Making CONNECTions With PGN-EDO51 Data Tracking to Mid-2024
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: PepGen, Inc.
Industry: Medical - Biomedical and Genetics
Company: PepGen, Inc.
Industry: Medical - Biomedical and Genetics
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: PepGen, Inc.
Industry: Medical - Biomedical and Genetics
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: PepGen, Inc.
Industry: Medical - Biomedical and Genetics
Company: PepGen, Inc.
Industry: Medical - Biomedical and Genetics
MOMENTUM Read Through: Thoughts on PEPG''s PGN-EDO51
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: PepGen, Inc.
Industry: Medical - Biomedical and Genetics
Bullish Ahead of CONNECT1-EDO51 in Mid-2024; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: PepGen, Inc.
Industry: Medical - Biomedical and Genetics
Company: PepGen, Inc.
Industry: Medical - Biomedical and Genetics
FDAs Lifting of Full Clinical Hold Validates Safety of Cell Penetrating Peptide Platform¯Implications for PGN-EDODM1
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: PepGen, Inc.
Industry: Medical - Biomedical and Genetics
CTA Clearance Might Help Accelerate PGN-EDODM1 Program
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: PepGen, Inc.
Industry: Medical - Biomedical and Genetics
HV Repeat Dosing Data Builds the Foundation for CONNECT1; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: PepGen, Inc.
Industry: Medical - Biomedical and Genetics
Making CONNECTions Happen; Phase 2 PGN-EDO51 Efforts On Track [2Q23 Highlights]
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: PepGen, Inc.
Industry: Medical - Biomedical and Genetics
Company: PepGen, Inc.
Industry: Medical - Biomedical and Genetics
DM1 Study Start Pushes Back As PEPG Awaits FDA Response
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: PepGen, Inc.
Industry: Medical - Biomedical and Genetics
DM1 Delay Disappointing But Manageable; Limited Read Through For Clinical Hold
Provider: Wedbush Securities Inc.
Analyst: CHOPRA R
Company: PepGen, Inc.
Industry: Medical - Biomedical and Genetics
Company: PepGen, Inc.
Industry: Medical - Biomedical and Genetics
Gene Therapy Criticisms a Boost for PGN-EDO51; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: PepGen, Inc.
Industry: Medical - Biomedical and Genetics
CONNECT-ing The Dots On Progress - PEPG Pipeline Advancing
Provider: Wedbush Securities Inc.
Analyst: CHICO L